Acquisition by John Sieckhaus of 92300 shares of Biosig Technologies at 0.2603 subject to Rule 16b-3
| BSGM Stock | USD 1.34 0.04 3.08% |
About 55% of BioSig Technologies,'s investors are presently thinking to get in. The analysis of overall sentiment of trading BioSig Technologies, Common otc stock suggests that some investors are interested at this time. BioSig Technologies,'s investing sentiment overview a quick insight into current market opportunities from investing in BioSig Technologies, Common. Many technical investors use BioSig Technologies, stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
BioSig Technologies, otc stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of BioSig daily returns and investor perception about the current price of BioSig Technologies, Common as well as its diversification or hedging effects on your existing portfolios.
BioSig |
Filed transaction by Biosig Technologies Officer Chief Operating Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
BioSig Technologies, Fundamental Analysis
We analyze BioSig Technologies,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioSig Technologies, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioSig Technologies, based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
BioSig Technologies, is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
BioSig Technologies, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioSig Technologies, otc stock to make a market-neutral strategy. Peer analysis of BioSig Technologies, could also be used in its relative valuation, which is a method of valuing BioSig Technologies, by comparing valuation metrics with similar companies.
Peers
BioSig Technologies, Related Equities
| TIVC | Tivic Health | 5.00 | ||||
| LUNG | Pulmonx Corp | 3.71 | ||||
| BMRA | Biomerica | 3.70 | ||||
| NPCE | Neuropace | 3.50 | ||||
| NMTC | Neuroone Medical | 2.70 | ||||
| INGN | Inogen | 2.05 | ||||
| APYX | Apyx Medical | 0.64 | ||||
| SRDX | SurModics | 0.40 | ||||
| BJDX | Bluejay Diagnostics | 1.54 | ||||
| XAIR | Beyond Air | 4.76 |
Other Information on Investing in BioSig OTC Stock
BioSig Technologies, financial ratios help investors to determine whether BioSig OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioSig with respect to the benefits of owning BioSig Technologies, security.